CSL Ltd (CSL)

Currency in AUD
168.30
-2.90(-1.69%)
Closed·
CSL is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
166.28171.54
52 wk Range
90.00222.47
Key Statistics
Bid/Ask
168.00 / 168.48
Prev. Close
171.2
Open
170
Day's Range
166.28-171.54
52 wk Range
90-222.47
Volume
2.69M
Average Volume (3m)
1.75M
1-Year Change
-22.2992%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CSL Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
163.02
Downside
-3.14%
Members' Sentiments
Bearish
Bullish
ProTips
Has raised its dividend for 4 consecutive years

CSL Ltd News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Sell
Moving Averages
Buy

Analyst Ratings

7 Buy
9 Hold
0 Sell
Ratings:
16 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 163.02
(-3.14% Downside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Citi
Hold160.00-4.93%110.00MaintainAug 20, 2026
CLSA
Buy180.00+6.95%130.00MaintainAug 19, 2026
UBS
Buy181.00+7.55%158.00MaintainAug 19, 2026
RBC Capital
Hold108.00-35.83%107.00MaintainJul 17, 2026
RBC Capital
Hold107.00-36.42%113.00MaintainJun 16, 2026

CSL Ltd Earnings Call Summary for H2/2026

  • CSL reported FY26 revenue of $15.8B (down 1%) and underlying NPAT-A of $3.1B (down 2%); statutory loss of $2.6B due to $6B in restructuring charges.
  • Shares surged 16.4% to $156.68 as company guided FY27 NPAT growth of ~5% despite flat revenue; authorized new AUD 1.1B buyback program.
  • CSL Behring expected to return to mid-single-digit growth on strong immunoglobulin demand; Vifor remains major drag with ~25% revenue decline forecast.
  • Company targeting $220M incremental savings in FY27, rising to $550M by FY28; maintaining dividend at $2.92/share with strong $3.5B operating cash flow.
  • Seqirus forecast for low-single-digit growth despite soft U.S. flu market; management emphasized plasma efficiency and portfolio simplification as key priorities.
Last Updated: 18/08/2026, 02:28
Read Full Transcript

Earnings

Latest Release
Aug 18, 2025
EPS / Forecast
2.04 / 2.70
Revenue / Forecast
7.08B / 10.2B
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS -5.35%
Dividend Yield
2.42%
Industry Median 1.94%
Annualised payout
4.07
Paid unevenly
5-Years Growth
+5.63%
Growth Streak

CSL Income Statement

Compare CSL to Peers and Sector

Metrics to compare
CSL
Peers
Sector
Relationship
P/E Ratio
−22.4x28.1x−0.3x
PEG Ratio
0.120.120.00
Price/Book
3.9x2.5x2.6x
Price / LTM Sales
3.7x2.7x3.1x
Upside (Analyst Target)
−4.8%39.1%47.6%
Fair Value Upside
Unlock11.3%5.6%Unlock

CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants. The CSL Seqirus segment manufactures, markets, and distributes influenza related products and pandemic services to governments. The CSL Vifor segment manufactures, markets, and distributes products in the therapeutic areas of iron deficiency and nephrology. The company’s therapeutic areas includes Immunoglobulins, Immunology, Immunology Haematology, Cardiovascular and Renal, and Vaccines. It also licenses CSL intellectual property. It also develops vaccines for the prevention of infectious disease. The company has strategic collaboration with Dutch biotech company VarmX BV for the development of VMX-C001 to help restore blood coagulation in patients requiring urgent surgery. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.

Employees
29000
Market
Australia

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
114.62M23.93%19.29B
Other Institutional Investors
73.98M15.45%12.45B
Public Companies & Retail Investors
290.31M60.62%48.86B
Total
478.91M100.00%80.6B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
State Street Investment Management8.24%39,466,3836,642,192
BlackRock, Inc.6.98%33,446,6875,629,077

People Also Watch

77.73
ZTS
+3.61%
231.52
RMD
+1.35%
71.22
WLSNc
+0.62%
128.48
NOW
-0.98%
61.87
CTSH
+1.56%

FAQ

What Is the CSL (CSL) Stock Price Today?

The CSL stock price today is 168.30 AUD.

What Stock Exchange Does CSL Trade On?

CSL is listed and trades on the Sydney Stock Exchange.

What Is the Stock Symbol for CSL?

The stock symbol for CSL is "CSL."

What Is the CSL Market Cap?

As of today, CSL market cap is 80.60B AUD.

What Is CSL's Earnings Per Share (TTM)?

The CSL EPS (TTM) is -5.35.

From a Technical Analysis Perspective, Is CSL a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has CSL Stock Split?

CSL has split 1 times.

How Many Employees Does CSL Have?

CSL has 29000 employees.

What is the current trading status of CSL (CSL)?

As of Aug 22, 2026, CSL (CSL) is trading at a price of 168.30 AUD, with a previous close of 171.20 AUD. The stock has fluctuated within a day range of 166.28 AUD to 171.54 AUD, while its 52-week range spans from 90.00 AUD to 222.47 AUD.

What Is CSL (CSL) Price Target According to Analysts?

The average 12-month price target for CSL is 163.02 AUD, with a high estimate of 204.79849393 AUD and a low estimate of 131.58555292 AUD. 7 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an -3.14% Downside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.